These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38756303)

  • 1. Gonadotropin-Releasing Hormone (GnRH) Agonists Do Not Protect Ovarian Function in Patients Undergoing Stem Cell Transplants.
    Benor A; Decherney A
    Cureus; 2024 Apr; 16(4):e58387. PubMed ID: 38756303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.
    Cheng YC; Takagi M; Milbourne A; Champlin RE; Ueno NT
    Oncologist; 2012; 17(2):233-8. PubMed ID: 22282904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of ovarian function and fertility despite gonadotoxic chemotherapy.
    Blumenfeld Z
    Expert Rev Endocrinol Metab; 2012 Sep; 7(5):567-576. PubMed ID: 30780892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
    Blumenfeld Z; Evron A
    Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice.
    Horicks F; Van Den Steen G; Gervy C; Clarke HJ; Demeestere I
    Mol Hum Reprod; 2018 Apr; 24(4):221-232. PubMed ID: 29438534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
    Blumenfeld Z; Patel B; Leiba R; Zuckerman T
    Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility after treatment for Hodgkin's disease.
    Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
    Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
    Blumenfeld Z
    Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian rescue/protection from chemotherapeutic agents.
    Blumenfeld Z
    J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing ovarian function and fertility following chemotherapy in premenopausal patients: Is there a role for ovarian suppression?
    Roof KA; Andre KE; Modesitt SC; Schirmer DA
    Gynecol Oncol Rep; 2024 Jun; 53():101383. PubMed ID: 38633671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
    Chen H; Xiao L; Li J; Cui L; Huang W
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
    Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
    Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.
    Saito S; Yamada M; Yano R; Takahashi K; Ebara A; Sakanaka H; Matsumoto M; Ishimaru T; Utsuno H; Matsuzawa Y; Ooka R; Fukuoka M; Akashi K; Kamijo S; Hamatani T; Tanaka M
    J Ovarian Res; 2023 Aug; 16(1):159. PubMed ID: 37563616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Blumenfeld Z; Zur H; Dann EJ
    Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity.
    Garrido-Oyarzún MF; Castelo-Branco C
    Climacteric; 2016 Dec; 19(6):522-525. PubMed ID: 27644002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.
    Del Castillo LM; Buigues A; Rossi V; Soriano MJ; Martinez J; De Felici M; Lamsira HK; Di Rella F; Klinger FG; Pellicer A; Herraiz S
    Hum Reprod; 2021 Aug; 36(9):2514-2528. PubMed ID: 34333622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility.
    Marder W; Fisseha S; Ganser MA; Somers EC
    Clin Med Insights Reprod Health; 2012 Oct; 2012(6):9-18. PubMed ID: 23970822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
    Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.
    Phelan R; Mann E; Napurski C; DeFor TE; Petryk A; Miller WP; Wagner JE; Verneris MR; Smith AR
    Bone Marrow Transplant; 2016 Oct; 51(10):1369-1375. PubMed ID: 27272448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.